Sign In
Buy CCXI
$13.86
-0.140 (-1.00%)
At Close: Jul 31, 2026
ChemoCentryx And Avacopan In ANCA-Associated Vasculitis: Making Amends
02:24pm, Tuesday, 24'th Aug 2021
Most expected CCXI to have achieved regulatory approval for avacopan to treat ANCA-Associated Vasculitis on July 7, 2021.
Are Options Traders Betting on a Big Move in ChemoCentryx (CCXI) Stock?
11:00am, Wednesday, 11'th Aug 2021
Investors need to pay close attention to ChemoCentryx (CCXI) stock based on the movements in the options market lately.
ChemoCentryx (CCXI) Q2 Loss Wider Than Expected, Sales Down
12:24pm, Tuesday, 10'th Aug 2021
ChemoCentryx Inc. (CCXI) reports a wider-than-expected loss in the second quarter and misses on sales.
ChemoCentryx, Inc. (CCXI) CEO Tom Schall on Q2 2021 Results - Earnings Call Transcript
11:03pm, Monday, 09'th Aug 2021
ChemoCentryx, Inc. (CCXI) CEO Tom Schall on Q2 2021 Results - Earnings Call Transcript
ChemoCentryx: Q2 Earnings Insights
05:36pm, Monday, 09'th Aug 2021
Shares of ChemoCentryx (NASDAQ:CCXI) rose in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share fell 293.10% year over year to ($0.56), which missed the e
ChemoCentryx to Participate in the Canaccord Genuity 41st Annual Growth Conference
08:30am, Wednesday, 04'th Aug 2021
SAN CARLOS, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in a fir
Analysts Estimate ChemoCentryx (CCXI) to Report a Decline in Earnings: What to Look Out for
04:46pm, Monday, 02'nd Aug 2021
ChemoCentryx (CCXI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ChemoCentryx to Hold Second Quarter 2021 Financial Results Conference Call on Monday, August 9, 2021
08:30am, Monday, 02'nd Aug 2021
MOUNTAIN VIEW, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's second quarter 2021 financial results will be released after market clos
2 Beaten-Down Biotech Stocks That Could Bounce Back
06:13am, Tuesday, 27'th Jul 2021
The market hasn't been kind to these two drugmakers, but both have a chance to turn things around.
ChemoCentryx: CRL Less Likely
11:04am, Sunday, 25'th Jul 2021
In my previous coverage, I said many analysts including myself thought a CRL was likely for avacopan. However, the FDA has accepted an amendment to the NDA and given an October 7 PDUFA date.
Is Now the Time to Buy ChemoCentryx Stock?
06:44am, Saturday, 10'th Jul 2021
Analysts following this risky biotech stock have changed their tune.
ChemoCentryx (CCXI) Files Amendment to NDA for Avacopan
10:32am, Wednesday, 07'th Jul 2021
ChemoCentryx (CCXI) files an amendment to its NDA for avacopan for treatment of ANCA-associated vasculitis. The new PDUFA date is Oct 7.
SAN DIEGO, July 7, 2021 /PRNewswire/ -- Johnson Fistel, LLP is investigating potential claims on behalf of ChemoCentryx Inc. ("ChemoCentryx" or the "Company") (NASDAQ: CCXI) against certain of its c
Why This ChemoCentryx Analyst Is Bullish
03:20pm, Tuesday, 06'th Jul 2021
H.C. Wainwright analysts remain bullish on ChemoCentryx, Inc. (NASDAQ:CCXI) following an amended new drug application for avacopan. The ChemoCentryx Analyst: Edward White reaffirmed a Buy rating on
ChemoCentryx Stock Is Approaching A Key Level
01:55pm, Tuesday, 06'th Jul 2021
ChemoCentryx Inc. (NASDAQ: CCXI) shares traded higher Tuesday after the company announced it filed an amendment to its New Drug Application for avacopan for the treatment of anti-neutrophil cytoplasmi
